A Phase 2 interventional study of ABP-450 in Cervical Dystonia, sponsored by AEON Biopharma, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-22.
Sponsored by AEON Biopharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Torticollis with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Torticollis · United States.
Among the 57 studies in Torticollis with a site in United States, this one is the 18th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2021, is one of 10 in phase 2, and was the 45th registered.
121 studies on the registry are indexed under Torticollis; 18 are open to participants now.
Browse Torticollis studies →7 of the 57 studies in Torticollis with a site in United States are open now. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–89
Vima Therapeutics · Sites in United States, Canada
Ages 18–70
Ipsen · Sites in United States, Czechia, France and 5 more countries
Ages 18–80
University of Minnesota · Sites in United States
Ages 30+ · Healthy volunteers
Virginia Commonwealth University · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Torticollis studies recruiting now, 4 (33%) set no upper age limit and 4 (33%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 7 · Phase 4 5
First in 2001; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is close to the median of 50 across 76 interventional studies indexed under Torticollis.
Median enrollment 45 across the 38 interventional studies, 44 across the 19 observational. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 57 have an industry lead sponsor. The 10 most frequent:
AEON Biopharma, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
AEON Biopharma, Inc. has 2 studies filed under Torticollis — fewer than ten, so there is no comparison to draw.
7 of the studies in Torticollis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07111663Vima TherapeuticsAn Observational Study of Individuals With Isolated Dystonia | 2026-11 |
| NCT07245615University of MinnesotaEffect of Vibro-tactile Stimulation Intensity on Head Posture in Cervical Dystonia | 2026-12-31 |
| NCT07304089Vima TherapeuticsA Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia | 2027-03 |
| NCT06937931IpsenA Study of IPN10200 for the Treatment of Cervical Dystonia in Adults | 2027-03-26 |
| NCT07140874University of FloridaZinc as an Adjunctive Therapy for Cervical Dystonia | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 57 studies in Torticollis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Open-label Extension trial will evaluate the safety and efficacy of ABP-450 for the treatment of cervical dystonia in adults. The study will enroll 60 patients across approximately 42 sites in the United States from Phase 2 (ABP-19000) trial. Study subjects who had their initial dose of study drug in the Phase 2 trial, irrespective of treatment allocation, will be eligible to enroll in this OLE study.
This Open-label Extension trial will evaluate the safety and efficacy of ABP-450 for the treatment of cervical dystonia in adults. The study will enroll 60 patients across approximately 42 sites in the United States from Phase 2 (ABP-19000) trial. Study subjects who had their initial dose of study drug in the Phase 2 trial, irrespective of treatment allocation, will be eligible to enroll in this OLE study. Study subjects will receive a predetermined dose of ABP-450 between the Low Dose and High Dose, based on the investigator's discretion and clinical judgment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABP-450 Between Low Dose and High Dose - Intramuscular injections into affected neck muscles with investigator's determined dose within the range of low dose and high dose - 4 injection cycles at 3-month intervals.
Drug: ABP-450
ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Also known as: prabotulinumtoxinA
Number of Participants With Treatment-related Serious Adverse Events
The primary safety endpoint will be the incidence of treatment-related serious adverse events since the start of treatment by Treatment Group when dosed with ABP-450 between Low Dose and High Dose.
Time frame: Up to 52 weeks
Mean Change in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score
The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scale is used to assess the severity of cervical Dystonia. The TWSTRS-total score has a minimum score of 0 and a maximum score of 85, where higher scores represent worse outcomes. It comprises 3 subscales, which are summated to get the total score: the Torticollis Severity Scale (minimum score of 0, maximum score of 35), the Disability Scale (minimum score of 0, maximum score of 30), and the Pain Scale (minimum score of 0, maximum score of 20).
Time frame: Four weeks after the dose of each cycle (4 cycles)
Mean Change in the Subscale Score of Severity of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
The Severity subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of torticollis in cervical dystonia. The severity subscale has a minimum score of 0 and maximum score of 35, where higher scores represent worse outcomes.
Time frame: Four weeks after the dose of each cycle (4 cycles)
Mean Change in the Subscale Score of Disability of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Spasmodic Torticollis Rating Scale (TWSTRS)
The Disability subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of disability in cervical dystonia. The disability subscale has a minimum score of 0 and maximum score of 30, where higher scores represent worse outcomes.
Time frame: Four weeks after the dose of each cycle (4 cycles)
Mean Change in the Subscale Score of Pain of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
The Pain subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of pain in cervical dystonia. The pain subscale has a minimum score of 0 and maximum score of 20, where higher scores represent worse outcomes.
Time frame: Four weeks after the dose of each cycle (4 cycles)
Mean Change in Patient Global Impression of Change (PGI-C)
The Patient Global Impression of Change (PGI-C) enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". For the analysis, the data was transformed to a linear 7 point scale where 1 = much better and 7 = much worse. The mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale was assessed by Treatment Group at Week 4.
Time frame: Four weeks after the dose of each cycle (4 cycles)
Mean Change in Clinical Global Impression of Change (CGI-C)
The Clinical Global Impression of Change (CGI-C) enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". For the analysis, the data was transformed to a linear 7 point scale where 1 = much better and 7 = much worse. The mean change from Baseline in the Clinical Global Impression of Change (CGI-C) Score was assessed by Treatment Group at Week 4.
Time frame: Four weeks after the dose of each cycle (4 cycles)
Participants who completed ABP-19000 study had the option to roll over to this ABP-19002 study at the same site they were previously enrolled.
| Milestone | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|
| Started | 25 | 17 | 9 |
| Completed | 18 | 15 | 7 |
| Not completed | 7 | 2 | 2 |
The primary safety endpoint will be the incidence of treatment-related serious adverse events since the start of treatment by Treatment Group when dosed with ABP-450 between Low Dose and High Dose.
| Participants | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|
| Number of Participants With Treatment-related Serious Adverse Events | 0 | 0 | 0 |
The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scale is used to assess the severity of cervical Dystonia. The TWSTRS-total score has a minimum score of 0 and a maximum score of 85, where higher scores represent worse outcomes. It comprises 3 subscales, which are summated to get the total score: the Torticollis Severity Scale (minimum score of 0, maximum score of 35), the Disability Scale (minimum score of 0, maximum score of 30), and the Pain Scale (minimum score of 0, maximum score of 20).
| units on a scale | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|
| Baseline | 41.58 ± 9.369 | 42.87 ± 6.631 | 45.63 ± 5.483 |
| Cycle 1, Week 4 | 27.54 ± 15.873 | 28.47 ± 12.743 | 34.17 ± 6.166 |
| Cycle 2, Week 4 | 31.17 ± 15.205 | 24.0 ± 12.808 | 23.71 ± 10.917 |
| Cycle 3, Week 4 | 28.19 ± 14.179 | 24.17 ± 12.302 | 24.82 ± 9.558 |
| Cycle 4, Week 4 | 31.45 ± 15.666 | 28.6 ± 11.967 | 27.75 ± 9.601 |
The Severity subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of torticollis in cervical dystonia. The severity subscale has a minimum score of 0 and maximum score of 35, where higher scores represent worse outcomes.
| units on a scale | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|
| Baseline | 18.8 ± 3.92 | 19.6 ± 2.71 | 22.3 ± 2.22 |
| Cycle 1, Week 4 | 12.6 ± 6.38 | 14.0 ± 4.97 | 19.3 ± 1.53 |
| Cycle 2, Week 4 | 15.3 ± 5.56 | 11.0 ± 6.55 | 14.4 ± 5.71 |
| Cycle 3, Week 4 | 12.1 ± 5.59 | 11.1 ± 6.44 | 13.6 ± 5.97 |
| Cycle 4, Week 4 | 12.6 ± 6.39 | 14.8 ± 4.96 | 15.8 ± 5.64 |
The Disability subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of disability in cervical dystonia. The disability subscale has a minimum score of 0 and maximum score of 30, where higher scores represent worse outcomes.
| units on a scale | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|
| Baseline | 11.2 ± 4.78 | 11.9 ± 4.17 | 12.5 ± 2.89 |
| Cycle 1, Week 4 | 6.9 ± 6.75 | 7.8 ± 5.29 | 9.0 ± 2.65 |
| Cycle 2, Week 4 | 8.8 ± 6.68 | 6.7 ± 5.43 | 5.0 ± 4.12 |
| Cycle 3, Week 4 | 9.1 ± 5.62 | 6.7 ± 4.58 | 5.4 ± 2.94 |
| Cycle 4, Week 4 | 9.6 ± 5.81 | 6.8 ± 5.71 | 6.2 ± 5.42 |
The Pain subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) is used to assess the severity of pain in cervical dystonia. The pain subscale has a minimum score of 0 and maximum score of 20, where higher scores represent worse outcomes.
| units on a scale | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|
| Baseline | 11.576 ± 3.0697 | 11.342 ± 3.0824 | 10.875 ± 2.7195 |
| Cycle 1, Week 4 | 8.060 ± 5.1386 | 6.639 ± 5.1071 | 5.833 ± 4.7719 |
| Cycle 2, Week 4 | 7.167 ± 5.3940 | 6.333 ± 3.8441 | 4.286 ± 2.9595 |
| Cycle 3, Week 4 | 6.938 ± 4.6209 | 6.348 ± 4.4573 | 5.821 ± 4.3702 |
| Cycle 4, Week 4 | 9.250 ± 4.5104 | 6.904 ± 3.9112 | 5.750 ± 2.7884 |
The Patient Global Impression of Change (PGI-C) enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". For the analysis, the data was transformed to a linear 7 point scale where 1 = much better and 7 = much worse. The mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale was assessed by Treatment Group at Week 4.
| units on a scale | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|
| Baseline | 3.8 ± 1.68 | 4.1 ± 1.35 | 3.8 ± 2.36 |
| Cycle 1, Week 4 | 2.1 ± 1.14 | 2.2 ± 1.17 | 1.7 ± 0.58 |
| Cycle 2, Week 4 | 2.2 ± 1.53 | 2.4 ± 1.63 | 1.6 ± 0.79 |
| Cycle 3, Week 4 | 1.8 ± 0.89 | 2.4 ± 1.47 | 1.9 ± 0.69 |
| Cycle 4, Week 4 | 1.8 ± 0.84 | 1.4 ± 0.77 | 2.0 ± 0.63 |
The Clinical Global Impression of Change (CGI-C) enables the patient to rate changes in their perception of their general health status over the duration of the assessment via a 7-point scale ranging from "much improved" to "much worse". The 7-point scale range is much improved (+3) to much worse (-3) with no change at "0". For the analysis, the data was transformed to a linear 7 point scale where 1 = much better and 7 = much worse. The mean change from Baseline in the Clinical Global Impression of Change (CGI-C) Score was assessed by Treatment Group at Week 4.
| units on a scale | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|
| Baseline | 3.4 ± 1.44 | 3.7 ± 1.37 | 3.8 ± 1.71 |
| Cycle 1, Week 4 | 2.1 ± 0.94 | 1.9 ± 0.94 | 1.7 ± 0.58 |
| Cycle 2, Week 4 | 2.5 ± 1.24 | 2.0 ± 1.52 | 1.7 ± 0.76 |
| Cycle 3, Week 4 | 2.1 ± 0.83 | 2.2 ± 1.15 | 1.9 ± 0.69 |
| Cycle 4, Week 4 | 2.0 ± 0.71 | 1.8 ± 0.60 | 1.8 ± 0.75 |
Collected over 52 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABP-450 - 150U | 0/25 (0%) | 0/25 (0%) | 16/25 (64%) |
| ABP-450 - 250U | 0/17 (0%) | 0/17 (0%) | 15/17 (88.2%) |
| ABP-450 - 350U | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Event | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U |
|---|---|---|---|
| COVID-19Infections and infestations | 6/25 | 4/17 | 1/9 |
| DysphagiaGastrointestinal disorders | 3/25 | 3/17 | 2/9 |
| VertigoEar and labyrinth disorders | 1/25 | 0/17 | 2/9 |
| Neck PainMusculoskeletal and connective tissue disorders | 2/25 | 3/17 | 0/9 |
| Injection site painGeneral disorders | 3/25 | 0/17 | 0/9 |
| NasopharyngitisInfections and infestations | 0/25 | 2/17 | 1/9 |
| SinusitisInfections and infestations | 1/25 | 2/17 | 0/9 |
| TorticollisMusculoskeletal and connective tissue disorders | 0/25 | 2/17 | 0/9 |
| ParesthesiaNervous system disorders | 1/25 | 2/17 | 0/9 |
| MigraineNervous system disorders | 0/25 | 2/17 | 0/9 |
| Age, Continuous(years) | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|
| Mean | 54.5 ± 12.72 | 58.0 ± 10.3 | 52.6 ± 11.96 | 55.3 ± 11.77 |
| Sex: Female, Male(Participants) | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|
| Female | 17 | 14 | 3 | 34 |
| Male | 8 | 3 | 6 | 17 |
| Ethnicity (NIH/OMB)(Participants) | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 0 | 6 |
| Not Hispanic or Latino | 21 | 15 | 9 | 45 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 2 |
| White | 22 | 16 | 9 | 47 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Region of Enrollment(participants) | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|
| United States | 25 | 17 | 9 | 51 |
| Weight (kg)(kg) | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|
| Mean | 78.71 ± 15.18 | 73.6 ± 15.69 | 98.66 ± 24.84 | 79.86 ± 18.65 |
| BMI(kg/m2) | ABP-450 - 150U | ABP-450 - 250U | ABP-450 - 350U | Total |
|---|---|---|---|---|
| Mean | 28.02 ± 4.69 | 27.22 ± 4.96 | 31.69 ± 6.18 | 28.28 ± 5.13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual Participant Data collected during the trial, after deidentification may be shared following review of the clinical study report by the FDA review division and if a decision is made to publish the results in a publication outside posting the results in clinicaltrials.gov
Ran from Jul 2021 to primary completion in Jul 2023, 23 months.
Results were first posted in Aug 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prabotulinumtoxin A
AEON Biopharma, Inc.